text:
Gallery: Upward Bound: LA Designers Create Happy Spaces for Homeless Fa...
A crowd that included actor/activist Don Cheadle gathered last week to celebrate the completion of the Upward Bound House Family Shelter in Culver City, Los Angeles, what is undeniably one of the prettiest and most cheerful homeless shelters we've ever seen. Once the site of a rundown motel with transient tenants, this 18-unit complex received a complete make over by an all-star cast of Los Angeles interior designers. With no budget at all, designers used their creative muscle to transform dark and dreary motel rooms into bright and uplifting spaces for homeless families in need.
6 Comments
February 18, 2010 at 5:29 pm
please contact me when you have an opening i hope soon because something is making me sick where i'm living and it's an emergency for my sake and my 18 yr old dauhter whose on campus
February 7, 2010 at 12:33 pm
Fabulous project – I would love to hear how the families enjoy their beautiful digs!
February 1, 2010 at 9:43 pm
Great post Haily! It was a wonderful experience and an incredibly supportive collaboration between the designers and vendor donors. I am honored to have been a part of this projec t.
February 1, 2010 at 9:35 pm
Hi this is Elizabeth Bomberger from InSight Interiors, one of the designers who worked on the Upward Bound project. You can see my design on the 1st picture of page 2 and the 2nd picture of page three of the article. If you liked my work and need a designer you may contact me at firstname.lastname@example.com. Thanks!


text:
The Bachelor
Bachelor 16 Flashback! Rachel Truehart, Jaclyn Swartz and More in Hair-Raising Photo
Despite the fact that they were all vying for the affections of one man, many of the ladies on The Bachelor Season 16 got pretty close. They must have had a lot of down time while the object of their affections, Ben Flajnik, was off somewhere skinny-dipping with Courtney Robertson.
However, we have no idea what shenanigans led to this particular photo op, featuring (left to right) Emily O'Brien, Elyse Myers, Jaclyn Swartz, Casey Shteamer, and Rachel Truehart. They look like a crew of Cindy Lou Whos from How The Grinch Stole Christmas!
Source: Jaclyn Swartz's Instagram

subset: commoncrawl


text:
College of Social Sciences and Humanities
Office of the Dean
420 Renaissance Park,
360 Huntington Avenue
Boston, MA 02115
Front Desk 617.373.5173
617.373.xxxx (for extensions listed below)
firstname.lastname@example.com / ext: 5841
Tim Cresswell, Associate Dean for Faculty Affairs, works with individuals across the college on mentoring of faculty members as well as on faculty hiring and promotion processes. Cresswell is a professor of history and international affairs and the associate director for public humanities at the Northeastern Humanities Center. A cultural geographer by training, he is the author or editor of eight books on the role of space, place, and mobility in social and cultural life. Cresswell holds PhDs in geography from the University of Wisconsin and in creative writing from Royal Holloway, University of London. Prior to coming to Northeastern in 2012, he was professor of geography at Royal Holloway.
email@example.com / ext: 2193
Chris Gallagher, Associate Dean for Teaching, Learning, and Experiential Education, holds a Ph.D. in writing, teaching, and criticism from University at Albany and a Master's degree in English from the University of New Hampshire. Joining the Dean's Office in July 2014, he works with colleagues throughout the college on researching and supporting the undergraduate learning experience; fostering excellence and innovation in teaching; refining curricula and assessment; and strengthening the connections between cutting-edge classroom work and experiential learning. Chris came to Northeastern in 2009 as Professor of English and Writing Program Director. Previously, he was Professor of English and Composition Coordinator at the University of Nebraska-Lincoln.
email@example.com / ext: 3482
Jack McDevitt, Associate Dean for Research and Graduate Studies, received both his Ph.D. in law, policy and society and his M.A. in public administration from Northeastern University, and his B.A. in political science from Stonehill College. Dr. McDevitt oversees research in the college, including proposal development and the administration of all externally funded research, and leads the college's graduate programs. He previously led the graduate program in the School of Criminology and Criminal Justice and headed the development of the Ph.D. in Criminology and Justice Policy. Dr. McDevitt also directs Northeastern's Institute on Race and Justice where he conducts research on hate crimes, racial profiling, gun violence, and human trafficking.
email@example.com / ext: 8882
Matthew Tobin, Associate Dean of Administration and Finance, holds a M.B.A. from Boston College and a B.S. from Babson College. In his leadership role, he works with colleagues in the college and throughout the university on administrative operations, financial activity, space, and information technology, as well as on setting and implementing strategy for CSSH. Matt arrived to Northeastern in 2015 with over 13 years of experience at Harvard University spanning all parts of the university. Most recently, he worked in Harvard's Office of Financial Strategy and Planning managing a portfolio of schools with a combined annual budget of $1.9 billion and acting as a close adviser to the university's leadership.
email@example.com / ext: x6812
Erika Koss, Assistant Dean for Research, Program Development, and Outreach, received her B.S. from the Master's College and an M.A. from San Diego State University. Her primary duties include creating, managing, and executing the programs for the Dean's Office; working with faculty members and graduate students on grant or fellowship proposals; and working on the development of further grant, fellowship, and program opportunities for college faculty and students. She has taught literature and writing at several colleges and universities in California and Maryland, most recently the United States Naval Academy in Annapolis. From 2005-2010, she worked at the National Endowment for the Arts, where she was a founding member of the creative teams for The Big Read and Poetry Out Loud.
firstname.lastname@example.com / ext: 4369
Mary Mello, Assistant Dean for the Undergraduate Academic Affairs, received her M.A. in English at Northeastern University. Mary primarily works with academic advising, admission yield efforts, retention, and cooperative education. Before working as an assistant dean, Mary held several different positions at Northeastern including Director of Academic Student Services for the College of Social Sciences and Humanities, and previously the College of Arts and Sciences.
email@example.com / ext: 4366
Amy Killeen, Director of Graduate Student Services, received her M.Ed. in college student development and counseling from Northeastern University and her B.A. in communications from The University of Connecticut. Amy specializes in graduate admissions, recruitment, commencement, academic policy, new degree and course proposals, monitoring student progress, and fulfilling data requests. Amy also volunteers her time at the Massachusetts Coalition for the Homeless and the Make-A-Wish Foundation of Massachusetts. In 2010, Amy was awarded the Unsung Heroine Award from the Massachusetts Commission on the Status of Women, and has been a past recipient of the President's Aspiration Award from Northeastern.
email@example.com / ext: 4361
Gayle Mackay, Director of Personnel Administration, received both a B.S. in business administration and an MBA from Northeastern University. She oversees all personnel functions for the college, including job postings and hiring; the annual merit process; performance management; personnel training; the tenure, promotion and sabbatical processes; and other personnel activities. She held a similar role in the College of Arts and Sciences following appointments in Human Resources Management and the College of Computer Science.
email@example.com / ext: 5427
Leslie Casey, Communications and Digital Strategy Manager, has a B.S. in communication from Boston University, a graduate certificate in business administration from Northeastern University, and is currently pursuing her M.B.A. at Northeastern. She oversees internal and external communication strategy at the Dean's Office, including coordinating with the Northeastern news team to identify feature news stories and faculty experts for media inquiries and pitches. Leslie is also responsible for the college's online presence, website development, and new media initiatives. She has held similar roles at the America East Conference and the Boston College Athletics Department.
firstname.lastname@example.com / ext: 5173
Melissa Newton, Administrative Assistant, graduated from Northeastern in 2011 with a B.A. in cultural anthropology and a minor in East Asian studies. Her varied background includes work at Bloomberg L. P. as a Japanese Finance Research Analyst, a native English teacher at the Amity English Conversion School in Himeji, and an import operations agent for Panalpina. Melissa is currently in a graduate program at Lesley University studying international higher education and international cultural relations.
email@example.com / ext: 7625
Dana Ritter, Finance and Administration Manager, oversees all departmental and program budgets, and works closely with the Associate Dean for Administration and Finance to project revenues and expenses. He joined the college in 2014 from the University of Massachusetts at Amherst, where he most recently served as the Chief Financial Manager for the College of Humanities and Fine Arts overseeing general business operations. He worked closely with department chairs and center directors to build and manage annual operating and capital budgets, partnered with the Dean to develop short- and long-term strategic plans, and served on the Chancellor's Budget Task Force.
email@example.com / ext: 5201
Tanya Robinson, Personnel Coordinator, received a B.S. in business management from Mount Ida College, a graduate certificate in human resources management from Emmanuel College, and an M.S. in management, with a concentration in human resources management, from Lasell College. She has extensive experience in human resources, and previously worked for MIT and Lasell College before bringing her experience to Northeastern in March, 2014. Tanya handles the part-time faculty hires, extra compensation forms, and all personnel matters for departments in the humanities.
firstname.lastname@example.com / ext: 5278
Andy Scott, Information Systems Coordinator, has worked at Northeastern University for over 25 years. Andy specializes in keeping computers running up to date and installing software, while also maintaining the network database for the Dean's Office. Prior to working at Northeastern, Andy worked at Dolby Laboratories researching noise reduction equipment.
firstname.lastname@example.com / ext: 5164
David Smikle, Executive Assistant to the Dean, received his B.A. in political science from the College of William and Mary and is currently pursuing an MBA at Northeastern University. His primary duties include developing systems to better support the Dean's administrative responsibilities, managing the Dean's calendar, and handling special projects. Prior to joining Northeastern, David was a paralegal at Iandoli & Desai, P.C., where he worked with a diverse clientele across a wide spectrum of immigration-related matters.
firstname.lastname@example.com / ext: 7498
Veena Teli, Post-Award Grant Specialist, has more than 21 years (with seven years in academia) of combined experience in human resources, recruitment, and office management. She has two master's degrees: one in statistics and one in computer science. Veena assists CSSH faculty members with all post-award needs such as reviewing, approving, and processing grant modifications, budget reconciliations, and no-cost extensions; maintaining an archive of college research accounts; providing financial projections; and maintaining overhead and start-up accounts. Before joining the CSSH Dean's Office in March, 2014, Veena worked at Northeastern as an Administrative Coordinator for VOTERS, a NIST grant in the Department of Civil and Environmental Engineering in the College of Engineering, since 2011.
firstname.lastname@example.com / ext: 4792
Carol Giusti-Cahalane, Director of Development, received her B.A. in psychology from Connecticut College. She is responsible for working with alumni who are interested in providing philanthropic support for CSSH. In this role, Carol helps alumni learn about the many opportunities available at CSSH to make a lasting impact for students, faculty, and programs. She connects potential donors with ideas and projects that match their philanthropic intent. Among the schools she has previously represented are Simmons College, Harvard Law School, and Providence College.
email@example.com / ext: 5464
Marybeth Savicki, Senior Officer for Corporate & Foundation Advancement, received a master's in clinical social work from Simmons College and her B.A. in American studies from Tufts. Marybeth is tasked with identifying, cultivating, soliciting and stewarding private institutional funding sources at the local, national and international level in support of the people and programs of CSSH and interdisciplinary university initiatives. Previously, she served as Director of Corporate Relations at Rice University in Houston, and worked as a development officer at both Tufts University and Dana-Farber Cancer Institute. Marybeth was also employed as a social worker serving adolescents and families for ten years and presently maintains her connection to the field as a volunteer.
email@example.com / ext: 5420
Peri Onipede, Director of Major Gifts, received her M.B.A. from IMD International, Switzerland, and her B.S. in computer information systems from Bentley University in Waltham, Massachusetts. She fundraises for the various departments and initiatives housed at CSSH from alumni, parents, and friends. Previously she worked at Boston University as Director of Development for the College of General Studies.
email@example.com / ext: 7413
Trish McElligott, Development Officer, works with the CSSH advancement team to expand the college's alumni outreach and engagement. She joined the Dean's Office in May 2015, but has a long history with Northeastern. Trish spent the previous five years with the University Advancement fundraising team, most recently as the project manager for the Individual Giving team. She is also an alumna and a parent of two current Northeastern students.


text:
Children's Park In the absence of a budget, the land identified for the children's park in the heart of Chamkhar town has remained idle and no plan has been drafted for it's development.
Bumthang dzongrab Sonam Tshering said the dzongkhag couldn't go ahead with the park, because no separate budget was allocated. He said, the dzongkhag would put up the budget in the next plan for land development.
The area, which is about 400 square feet, is fenced but has no facilities for the children.
Initially, there was a plan to have a prayer wheel in the centre of the park, along with other facilities.
Town representative Karma Legden said there was neither budget from the dzongkhag, nor were any sponsors willing to support the park's development. An official from the dzongkhag municipal office said there was even a plan to plant grass in the area.
With the fenced area idle, the town's children are seen playing in the nearby taxi parking and along the roads. But this has worried parents, because the area has no parking facilities.
A parent, who runs a shop in the town, said it is important to have such facilities, because many children use roads for their entertainment. "There's a high chance of accidents occurring, with both children and vehicles moving around in the same area," she said.
By Tashi Tenzin


text:
Robin Thicke's "Love After War," is pretty clearly about a relationship, although the title is rather pertinent following the end of the Iraq War yesterday. Last night on The Tonight Show With Jay Leno, Robin Thicke performed the sexy song — and we think if his voice was reincarnated as a physical thing it would be bedroom eyes. (Speaking of bedroom eyes, why are you hiding them with those sunglasses at night, Robin?) Either way, his performance of the title track off his new LP was vibrant, and Thicke laid on the signature charm that has all the ladies swooning, as we saw at his live show in New York last week.
The Tastemakers At Pitchfork Declare The Top 100 Tracks Of 2011
The strangest thing is looking a "Best Of 2011″ list and not seeing Adele in the Top 10. It's almost refreshing, although we do love Adele. In fact, Adele doesn't appear until #23 on Pitchfork's Top 100 Tracks Of 2011 list, which is quite unsettling given that "Rolling In The Deep" was pivotal in defining 2011 popular music landscape ("Someone Like You" appears at #60). But we guess that's what makes Pitchfork tastemakers — they don't follow trends, yet are willing to give credit where credit is due.
More unexpectedly still, Nicki Minaj makes it to #4 on Pitchfork's list for "Super Bass" — a huge party track that slipped almost completely under the radar on this year's critical end of year lists. However, the only surprise about Bon Iver's "Holocene" coming it at #2 is that it wasn't #1, lending a painfully predictable air to the inclusion. Most importantly however, coming it at number one is the forgotten hit of the year, the confusingly underrated "Midnight City" by M83. We're predicting that M83 will be to 2012 what Bon Iver was to 2011, so it makes sense that Pitchfork would deem the electronic master piece a number one. We're also pretty stoked to see Beyoncé at #7 with "Countdown" — probably the most overlooked track of the year.
The Top 100 Tracks [Pitchfork]
It's That Time Of Year: Paste Releases Their Top 50 Albums Of 2011
Another year, another 50 albums you need to know, according to Paste Magazine. Yep, 2011 is coming to a close, and we're about to be slammed with the "tops" and the "bests" of the year, not to mention the "musts" and the "watch this spaces" for 2012. Paste Magazine has kicked off the festivities with their top 50 favorite albums of 2011, and while 50 seems like a big number, it's certainly not enough.
We've been drooling over the list, which lists Bon Iver's Bon Iver, Bon Iver as the best album of the year, but also includes VH1 favorites like Adele (#14), My Morning Jacket (#3) and even You Oughta Know artist Dawes (#8). However, we ask, where praytell is Beyoncé? We implore! And what of Watch The Throne?
Of the lesser knowns, how could Youth Lagoon, The Weeknd and Atlas Sound fail to make the cut? It's been a big year indeed, and it looks like culling a list down to even a generous 50 is a ruthless task. Hats off to Paste Magazine for taking a decisive plunge into rating 2011's vast and amazing releases.
Check out their complete list below the jump.
Tuned In: M83's "Midnight City" Soars On Fallon
M83's lead single from their new album Hurry Up, We're Dreaming has an almost unstoppable momentum behind it, and it's not showing any sign of slowing down. The song has already appeared on a Victoria's Secret commercial and on the end credits for HBO's How To Make It In America, and last night the band performed the electronic hit live on Late Night With Jimmy Fallon. On stage last night (after being introduced by a giddy Fallon) M83 gave an energetic performance — we never thought that watching electronic music live could be so compelling. There was even live saxophone, and we've got to say, it's rare that we've seen a saxophonist rock that hard!
M83's "Midnight City" Sees The Victoria's Secret Angels Come Out To Play
M83's new album, Hurry Up We're Dreaming, has been one of the most talked about releases of 2011, and has launched the band from cult indie-electro status to "next big thing" stature. And the first single from the album, "Midnight City", appears to be the culprit behind M83's sudden pervasiveness. As the soundtrack to Victoria's Secret's latest launch — the landing of the newest Angels in tandem with the release of the brand's new fragrance — "Midnight City" has blasted out of it's alternative niche and right into the hungry ears of mainstream audiences.
And the buck doesn't stop there — "Midnight City" was also featured as the credits rolled on Sunday night's episode of HBO's How To Make It In America. It's not entirely surprising that M83's star has risen so quickly, given the band's brand of uplifting, huge, reverberating sounds. The music is almost made to play over grand montages of sweeping movements, slow motion running and whimsical moments. We're expecting to see more M83 blasting over vast, panning cameras and epic movie style drama very soon!


text:
Quality CareFind out why Mayo Clinic is the right place for your health care. Make an appointment.
Meet the StaffFind a directory of doctors and departments at all Mayo Clinic campuses. Visit now.
Research and Clinical TrialsSee how Mayo Clinic research and clinical trials advance the science of medicine and improve patient care. Explore now.
Visit Our SchoolsEducators at Mayo Clinic train tomorrow's leaders to deliver compassionate, high-value, safe patient care. Choose a degree.
Professional ServicesExplore Mayo Clinic's many resources and see jobs available for medical professionals. Get updates.
Give to Mayo ClinicHelp set a new world standard in care for people everywhere. Give now.
Below are current clinical trials.
Filter this list of studies by location, status and more.
Rochester, Minn.
Describes the nature of a clinical study. Types include:
RATIONALE: Breast-conserving surgery is a less invasive type of surgery for breast cancer and may have fewer side effects and improve recovery. Radiation therapy uses high-energy x rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This phase II trial studies how well breast-conserving surgery and radiation therapy work in treating patients with multiple ipsilateral breast cancer
Study statuses change often. Please contact us for help.
Contact us for the latest status
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.
The investigator's global hypothesis is that women with Polycystic Ovary Syndrome (PCOS) can be separated into subtypes based on their response to metformin. The investigators propose here to use both targeted and non-targeted metabolomic approach to identify pathways associated with metformin's effect on insulin sensitivity and endothelial function. This pilot project will be the foundation for developing tailored therapeutic approaches to Polycystic Ovary Syndrome and identifying novel drug targets.
Open for enrollment
In the southwest region of Alaska where the project takes place, 79% of Alaska Native women smoke cigarettes or use smokeless tobacco (ST) during pregnancy. In addition, pregnancy appears to be a high risk period for initiation of tobacco use, primarily ST, among women reporting no use of tobacco 3 months before pregnancy. Intervention efforts targeting the entire community, not only pregnant women, to address social norms about tobacco use may be effective. Thus, the investigators will evaluate the efficacy of a novel, multi-component, theory-based intervention for reducing tobacco use during pregnancy, incorporating both individually targeted and community level components delivered by female elders "Native Sisters." The intervention builds on effective community and individual-based approaches for tobacco cessation and lay health advisor approaches for cancer prevention among Native American women. As part of the intervention, a social marketing campaign including digital stories and other small media will be developed with community feedback. Individually targeted components will be six 30-40 minute telephone or home-based peer counseling sessions with pregnant women.
Increased mammographic density is recognized as an important risk factor for developing breast cancer, however, the underlying mechanism explaining this relationship is unclear. The investigators hypothesize that Molecular Breast Imaging (MBI) can more accurately distinguish dense tissue on mammography which is at high risk from dense tissue at low risk by indicating cellular activity in dense tissue as radiotracer uptake (functional density) in the breast. In this pilot study, the investigators want to compare the histological characteristics of breast tissue in patients with who have similar density on mammography but different levels of functional density on MBI.
The purpose of this study is to show that improvements in the molecular breast imaging (MBI) technology will allow reduction of the administered dose of Tc-99m sestamibi while maintaining a sensitivity of 90% for tumor detection.
This phase I trial studies the side effects and best dose of veliparib when given together with floxuridine in treating patients with metastatic epithelial ovarian, primary peritoneal cavity, or fallopian tube cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as floxuridine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving veliparib together with floxuridine may kill more tumor cells.
This is an open label, single-arm, phase II study. The study population is adult patients with asymptomatic recurrent ovarian cancer who have an elevation in their CA-125 level.
This pilot clinical trial studies the safety and immunogenicity of vaccine therapy in treating patients with stage IIIC-IV ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer following surgery and chemotherapy. Vaccines made from a person's peptide treated white blood cells may help the body build an effective immune response to kill tumor cells.
Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.
This randomized phase II trial studies how well tamoxifen citrate works compared with z-endoxifen hydrochloride in treating patients with breast cancer that has spread to nearby tissue or lymph nodes or other parts of the body and has estrogen receptors but not human epidermal growth factor receptor 2 (HER2) receptors on the surface of its cells. Estrogen can cause the growth of tumor cells. Hormone therapy using tamoxifen citrate or z-endoxifen hydrochloride may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether tamoxifen citrate or z-endoxifen hydrochloride is more effective in treating patients with breast cancer.
This study is designed to determine whether an oral perioperative medication (alvimopan--a selective mu antagonist) improves bowel recovery over placebo after surgery for ovarian cancer.
Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below.
Mayo Clinic is a not-for-profit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.


text:
Hold down Control (PC) or Command (Mac) key + mouseclick to select more than one option
|Avg. Dinner Entrée
|Greater than $25
|$18.01 - $25
|$12.01 - $18
|$7.01 - $12
|Less than $7
Posted by markino italy on 03/06/2012
I used to go frequently..but after the last dinner i had there i will not anymore. The reason is the ridiculous amount of food in the appetizer i had . My girlfriend had the cheese appetizer and it was really a scandal! Poor in the presentation and the cheese was soo little it was looking like they they cut the smallest piece at the bottom of it ... Problem is that the place is expensive and look like they are saving money on you. They must have a profit close to 10 times the value of the plate!
Posted by Anonymous on 03/13/2011
Went here after discovering my old standby east village Italian had closed. The place is nice and the service was decent, BUT -- got the eggplant antipasti - it was good, but come on, one small slice of eggplant for $11 -- since when is eggplant so precious? The gorgonzola salad had no gorgonzola cheese, the seafood in the Spaghetti Allo Scoglio was ALL overcooked, and the cannellini beans with olive oil side order was canned beans They gave us the check before asking if we wanted coffee or dessert (even though no one was waiting for a table...) Save your money - There are too many really good restaurants in that neighborhood
Posted by Boots on 10/21/2010
Me and my husband went here for our anniversary and almost did not go in because no one was in there. Until we went out to their beautiful garden and it was packed. He had the gnocchi with gin and crab meat, TO DIE FOR! I had the shrimp risotto which was amazing! It was pricey so we can only go there on special occassions, so now I need to come up with some excuses! We also had a dessert of pear and apple pie with vanilla ice cream... delicious!
Posted by sj on 06/10/2010
First time dining here. Perhaps the preparers were having a bad night. The appetizers didn't have any salt, while my seafood stew was so incredibly salty that I wasn't able to finish it. May try it one more time in the future just in case it was a one-off event.
Posted by annoymous on 03/07/2010
I celebrated my birthday here and everything about our experience was fantastic- from the delicious pastas, to the attentive and helpful staff to the convivial atmosphere. I will definitely be going back and highly recommend this restaurant!
Posted by Lipton on 12/29/2009
The food was pretty good. We had the gnocchi and a lobster pasta special and both were great. The carpaccio appetizer had some olive oil on it that made it stick to the plate. The prices were decent - just over $100 (not incl. tip) for 2 entrees, 2 appetizers and a bottle of wine. The service was absolutely amazing. Everyone seemed very interested in ensuring that we had an enjoyable experience.
Posted by love to eat on 09/07/2009
The seafood stew is incredible. I think my husband and I will be back for eat at least once a month. In fat all of the food here is wonderful and the service is great. Very cute place and if you can get a table int he garden you are super lucky - it's beautiful!


text:
A wireless network is an essential part of every digital home. Without one, spouses will be left sobbing on their disconnected iPads, children will curse their lack of multiplayer mayhem, and you'll be left refreshing TechRadar wondering where all the stories have gone.
Choosing a new router isn't easy. Modern routers offer a lot of high-end features including DLNA media streaming, NAS capabilities, remote sharing features, guest networks, IPv6, and more besides. That's on top of the more straightforward 802.11n wireless connectivity, Ethernet ports and broadband capabilities. So what exactly should you be looking for?
Currently 802.11n is the base wireless standard and it will run at least a 2.4GHz 2x2 300Mbps antenna. That last part is important - more advanced router models provide a 3x3 antenna array and a faster 450Mbps throughput
Are you 802.11ac compatible?
To complicate things further, a second 5GHz wireless band is now available, which can technically improve wireless speeds under the right conditions. Around the techno-corner, a newer and much faster wireless standard known as 802.11ac is being finalised. It is already widely available in routers despite only being available in a few laptop models.
Besides core wireless networking, many routers offer an integrated broadband connection. Basic models provide a cable DSL port, which will plug into an existing broadband modem. More expensive models can offer an ADSL2+ modem or for new fibre services a VDSL modem up to 100Mbps.
If you're hoping to replace an existing ISP supplied model either because it's broken and out of warranty, or it only offers poor wireless support, then ensure that you replace it with a model that supports your current broadband connection. Perhaps one of these clever routers will catch your eye…
1. Asus RT-N66U
The RT-N66U 'Dark Knight' is Asus' first N900 router and it's the feature-rich follow up to the highly popular and award-winning Asus RT-N56U, which can still be picked up for a lower price. This update comes with increased Wi-Fi speeds of up to 450Mbps on both the 5GHz and 2.4GHz bands concurrently - hence the N900 name.
This makes it ideal for bandwidth hungry tasks like 3D HD video streaming and multiplayer gaming, while at the same time still enabling you to surf the web and download/share files. It's also jam-packed with features such as a built in VPN server, a firewall that you can customise, QoS and IPv6 support.
2. Linksys EA6500
What is the Linksys EA6500 packing? It has six antenna, so it's a full 3x3 450Mbps 802.11n 2.4GHz and 5GHz dual-band router with the added ability for 1300Mbps 5GHz 802.11ac. There are also four Gigabit LAN ports, plus WAN and two USB 2.0 ports with printer, DLNA and NAS capabilities.
The Linksys aced all of our speed tests but it also fell foul of a highly irritating cloud registration system - you'll see people protesting this at length online. But thankfully, since we first looked at the EA6500, this annoyance has been removed. So you can just get on and enjoy unprecedented speed!
Read our Linksys EA6500 review
3. Netgear D6300
Wireless 802.11ac draft routers are coming out thick and fast, and the Netgear D6300 802.11ac dual band gigabit Wi-Fi modem router is in fact an ADSL2+ equipped version of the Netgear R6300, which is equally well-worth checking out.
For UK and European countries that largely use copper-based ADSL, rather than cable DSL, this represents the first all-in-one device that can provide a complete communication solution from a single unit. It's the stuff of dreams for the purist and for people who hate cables.


text:
Two super-charged performances of "Cut Me Some Slack" and one leaked studio version later, we are fully prepared to accept what was totally unthinkable not one week ago: that the Paul McCartney/Nirvana collaboration is a real and rocking thing.
When word of the team-up first broke last week, there were cries of heresy — Courtney Love, reasonably distressed by the thought of a Kurt Cobain-less Nirvana, leading that charge — and implausibility, but then Dave Grohl, Krist Novoselic and Pat Smear (aka the surviving members of Nirvana) all showed up with Macca to play their new song at the 12-12-12 Concert for Sandy Relief and it rocked so hard that it seemed totally reasonable to cut them some slack, if you will.
The new crew turned up again over the weekend, performing "Cut Me Some Slack" underneath tinsel and besides a Christmas tree on Saturday Night Live, and and handily killing it once more and making it even harder for us to deny that this whole McVana thing might actually be sort of awesome. And then the very good studio-version that found its way to the internet this weekend and now we know for sure that this collaboration is a thing we love, most of all because of that nice moment halfway through the song when the harmony hits and breathes a little Beatles into the otherwise shattering rock song. Consider our calenders marked for Grohl's forthcoming Nirvana documentary Sound City, which is slated to feature "Cut Me Some Slack" on the soundtrack.
Macca also played "My Valentine" off his recent Kisses on The Bottom:
And perhaps topping all was the show's opening tribute to the victims of the Sandy Hook shooting, which had New York City Children's Choir's singing "Silent Night" and our stomachs in a knot:


text:
Plan Your Wedding with local knowledge from recent newlyweds
Discover real weddings, venue and vendor
reviews, and so much more, in your local area:
reviews, and so much more, in your local area:
RECENT ACTIVITY in other local areas
Read the buzz in other cities around the world!
San Juan, Puerto Rico316 engaged couples/newlyweds in San Juan are using Wedding Mapper!
10 replies 351 viewsLatest Topic: Videographer for Old San Juan Wedding
Last Message: Jul. 18, 2015
Cartagena, Bolivar, Colombia341 engaged couples/newlyweds in Cartagena are using Wedding Mapper!
8 replies 203 viewsLatest Topic: Destination Wedding
Last Message: Jul. 15, 2015
Spokane, WA, USA212 engaged couples/newlyweds in Spokane are using Wedding Mapper!
16 replies 7703 viewsLatest Topic: places to get married
Last Message: Jul. 13, 2015
Dallas, TX, USA1087 engaged couples/newlyweds in Dallas are using Wedding Mapper!
1 reply 137 viewsLatest Topic: I need a final stages wedding planner
Last Message: Jul. 07, 2015
Wausau, WI, USA123 engaged couples/newlyweds in Wausau are using Wedding Mapper!
5 replies 780 viewsLatest Topic: wedding venue
Last Message: Jul. 06, 2015
San Juan, Puerto Rico316 engaged couples/newlyweds in San Juan are using Wedding Mapper!
9 replies 310 viewsLatest Topic: Restaurant for Rehearsal Dinner - Old San Juan
Last Message: Jul. 02, 2015
TOP VENDORS around the world
Wce Carriagehouse
Englewood, NJ
Mi Boda En Cartagena
Cartagena de Indias, Colombia
Marci Curtis - Wedding P...
Troy, MI


text:
Pharming (genetics)
- For pharming in internet, see pharming. For pharming in drug abuse, see pharming parties
Pharming is a portmanteau of farming and "pharmaceutical" and refers to the use of genetic engineering to insert genes that code for useful pharmaceuticals into host animals or plants that would otherwise not express those genes, thus creating a genetically modified organism (GMO).[1][2] Pharming is also known as molecular farming, molecular pharming[3] or biopharming.[4]
The products of pharming are recombinant proteins or their metabolic products. Recombinant proteins are most commonly produced using bacteria or yeast in a bioreactor, but pharming offers the advantage to the producer that it does not require expensive infrastructure, and production capacity can be quickly scaled to meet demand, at greatly reduced cost.[5]
The first recombinant plant-derived protein (PDP) was human serum albumin, initially produced in 1990 in transgenic tobacco and potato plants.[6] Open field growing trials of these crops began in the United States in 1992 and have taken place every year since. While the United States Department of Agriculture has approved planting of pharma crops in every state, most testing has taken place in Hawaii, Nebraska, Iowa, and Wisconsin.[7]
In the early 2000s, the pharming industry was robust. Proof of concept has been established for the production of many therapeutic proteins, including antibodies, blood products, cytokines, growth factors, hormones, recombinant enzymes and human and veterinary vaccines.[8] By 2003 several PDP products for the treatment of human diseases were under development by nearly 200 biotech companies, including recombinant gastric lipase for the treatment of cystic fibrosis, and antibodies for the prevention of dental caries and the treatment of non-Hodgkin's lymphoma.[9]
Several proteins were brought to market as research and bioproduction reagents, mostly by Sigma-Aldrich. ProdiGene struck agreements with Sigma to distribute ProdiGene's corn-produced aprotinin, trypsin,[10] beta-glucuronidase (GUS), and avidin. Large Scale Biology and SIgma agreed that Sigma would distribute LSBC's tobacco-produced aprotinin. Sigma also agreed to distribute Ventria's rise-produced Lactoferrin and Lysozyme.
However in late 2002, just as ProdiGene was ramping up production of trypsin for commercial launch[11] it was discovered that volunteer plants (leftover from the prior harvest) of one of their GM corn products were harvested with the conventional soybean crop later planted in that field.[12] ProdiGene was fined $250,000 and ordered by the USDA to pay over $3 million in cleanup costs. This raised a furor and set the pharming field back, dramatically.[5] Many companies went bankrupt as companies faced difficulties getting permits for field trials and investors fled.[5] In reaction, APHIS introduced more strict regulations for pharming field trials in the US in 2003.[13] In 2005, Anheuser-Busch threatened to boycott rice grown in Missouri because of plans by Ventria Bioscience to grow pharm rice in the state. A compromise was reached, but Ventria withdrew its permit to plant in Missouri due to unrelated circumstances.
The industry has slowly recovered, by focusing on pharming in simple plants grown in bioreactors and on growing GM crops in greenhouses.[14] Some companies and academic groups have continued with open-field trials of GM crops that produce drugs. In 2006 Dow AgroSciences received USDA approval to market a vaccine for poultry against Newcastle disease, produced in plant cell culture - the first plant-produced vaccine approved in the U.S.[15][16]
Pharming in mammals[edit]
Milk is presently the most mature system to produce recombinant proteins from transgenic organisms. Blood, egg white, seminal plasma, and urine are other theoretically possible systems, but all have drawbacks. Blood, for instance, as of 2012 cannot store high levels of stable recombinant proteins, and biologically active proteins in blood may alter the health of the animals.[17] Expression in the milk of a mammal, such as a cow, sheep, or goat, is a common application, as milk production is plentiful and purification from milk is relatively easy. Hamsters and rabbits have also been used in preliminary studies because of their faster breeding.
One approach to this technology is the creation of a transgenic mammal that can produce the biopharmaceutical in its milk (or blood or urine). Once an animal is produced, typically using the pronuclear microinjection method, it becomes efficacious to use cloning technology to create additional offspring that carry the favorable modified genome.[18] In February 2009 the US FDA granted marketing approval for the first drug to be produced in genetically modified livestock.[19] The drug is called ATryn, which is antithrombin protein purified from the milk of genetically modified goats. Marketing permission was granted by the European Medicines Agency in August 2006.[20]
Pharming in plants[edit]
Plant-Made Pharmaceuticals (PMPs), also referred to as pharming, is a sub-sector of the biotechnology industry that involves the process of genetically engineering plants so that they can produce certain types of therapeutically important proteins and associate molecules such as peptides and secondary metabolites. The proteins and molecules can then be harvested and used to produce pharmaceuticals.
Recently, several non-crop plants such as the duckweed Lemna minor or the moss Physcomitrella patens have shown to be useful for the production of biopharmaceuticals. These frugal organisms can be cultivated in bioreactors (as opposed to being grown in fields), secrete the transformed proteins into the growth medium and, thus, substantially reduce the burden of protein purification in preparing recombinant proteins for medical use.[21][22][23] In addition, both species can be engineered to cause secretion of proteins with human patterns of glycosylation, an improvement over conventional plant gene-expression systems.[24][25] Biolex Therapeutics developed a duckweed-based expression platform; it sold that business to Synthon and declared bankruptcy in 2012.
Additionally, an Israeli company, Protalix, has developed a method to produce therapeutics in cultured transgenic carrot or tobacco cells.[26] Protalix and its partner, Pfizer, received FDA approval to market its drug, Taliglucerase alfa (Elelyso), treatment for Gaucher's Disease, in 2012.[27]
Arabidopsis is often used as a model organism to study gene expression in plants, while actual production may be carried out in maize, rice, potatoes, tobacco, flax or safflower. The advantage of rice and flax is that they are self-pollinating, and thus gene flow issues (see below) are avoided. However, human error could still result in pharm crops entering the food supply. Using a minor crop such as safflower or tobacco, avoids the greater political pressures and risk to the food supply involved with using staple crops such as beans or rice. Despite these risks, corn and soybeans are currently the most common crops that are being used in field trials to produce pharmaceuticals.[citation needed]
The regulation of genetic engineering concerns the approaches taken by governments to assess and manage the risks associated with the development and release of genetically modified crops. There are differences in the regulation of GM crops - including those used for pharming - between countries, with some of the most marked differences occurring between the USA and Europe. Regulation varies in a given country depending on the intended use of the products of the genetic engineering. For example, a crop not intended for food use is generally not reviewed by authorities responsible for food safety.
Controversy over pharming[edit]
There are controversies around GMOs generally on several levels, including whether making them is ethical, issues concerning intellectual property and market dynamics; environmental effects of GM crops; and GM crops' role in industrial agricultural more generally. There are also specific controversies around pharming.
Plants do not carry pathogens that might be dangerous to human health. Additionally, on the level of pharmacologically active proteins, there are no proteins in plants that are similar to human proteins. On the other hand, plants are still sufficiently closely related to animals and humans that they are able to correctly process and configure both animal and human proteins. Their seeds and fruits also provide sterile packaging containers for the valuable therapeutics and guarantee a certain storage life.[28]
Global demand for pharmaceuticals is at unprecedented levels. Expanding the existing microbial systems, although feasible for some therapeutic products, is not a satisfactory option on several grounds.[8] Many proteins of interest are too complex to be made by microbial systems or by protein synthesis.[6][28] These proteins are currently being produced in animal cell cultures, but the resulting product is often prohibitively expensive for many patients. For these reasons, science has been exploring other options for producing proteins of therapeutic value.[2][8][16]
These pharmaceutical crops could become extremely beneficial in developing countries. The World Health Organization estimates that nearly 3 million people die each year from vaccine preventable disease, mostly in Africa. Diseases such as measles and hepatitis lead to deaths in countries where the people cannot afford the high costs of vaccines, but pharm crops could help solve this problem.[29]
While molecular farming is one application of genetic engineering, there are concerns that are unique to it. In the case of genetically modified (GM) foods, concerns focus on the safety of the food for human consumption. In response, it has been argued that the genes that enhance a crop in some way, such as drought resistance or pesticide resistance, are not believed to affect the food itself. Other GM foods in development, such as fruits designed to ripen faster or grow larger, are believed not to affect humans any differently from non-GM varieties.[2][16][28][30]
In contrast, molecular farming is not intended for crops destined for the food chain. It produces plants that contain physiologically active compounds that accumulate in the plant's tissues. Considerable attention is focused, therefore, on the restraint and caution necessary to protect both consumer health and environmental biodiversity.[2]
The fact that the plants are used to produce drugs alarms activists. They worry that once production begins, the altered plants might find their way into the food supply or cross-pollinate with conventional, non-GM crops.[30] These concerns have historical validation from the ProdiGene incident, and from the StarLink incident, in which GMO corn accidentally ended up in commercial food products. Activists also are concerned about the power of business. According to the Canadian Food Inspection Agency, in a recent report, says that U.S. demand alone for biotech pharmaceuticals is expanding at 13 percent annually and to reach a market value of $28.6 billion in 2004.[30] Pharming is expected to be worth $100 billion globally by 2020.[31]
List of originators (companies and universities) and research projects and products[edit]
Please note that this list is by no means exhaustive.
- Dow AgroSciences - poultry vaccine against Newcastle disease virus (first PMP to be approved for marketing by the USDA Center for Veterinary Biologics[32] Dow never intended to market the vaccine.[33] "'Dow Agrosciences used the animal vaccine as an example to completely run through the process. A new platform needs to be approved, which can be difficult when authorities get in contact with it for the first time', explains the plant physiologist Stefan Schillberg, head of the Molecular Biology Division at the Fraunhofer Institute for Molecular Biology and Applied Ecology Aachen."[34]
- Fraunhofer Institute for Molecular Biology and Applied Ecology, with sites in Germany, the US, and Chile[35] is the lead institute of the Pharma Planta consortium of 33 partner organizations from 12 European countries and South Africa, funded by the European Commission.[36] Pharma Planta is developing systems for plant production of proteins in greenhouses in the European regulatory framework.[37] It is collaborating on biosimilars with Plantform and PharmaPraxis (see below).[38]
- Genzyme - antithrombin III in goat milk
- GTC Biotherapeutics - ATryn (recombinant human antithrombin) in goat milk[39]
- Icon Genetics produces therapeutics in transiently infected Nicotiana benthamiana (relative of tobacco) plants in greenhouses in Halle, Germany[40][41] or in fields. First product is a vaccine for a cancer, non-Hodgkin's lymphoma.[41]
- Iowa State University - immunogenic protein from E. coli bacteria in pollen-free corn as a potential vaccine against E. coli for animals and humans[42][43][44]
- Kentucky Bioprocessing took over Large Scale Biology's facilities in Owensboro, Kentucky, and offers contract biomanufacturing services in tobacco plants, grown in greenhouses or in open fields.[45]
- Medicago Inc. - Pre-clinical trials of Influenza vaccine made in transiently infected Nicotiana benthamiana (relative of tobacco) plants in greenhouses[46] Medicago has a system for pharming in alfalfa that their website says is "not suited for the production of vaccines"[47]
- PharmaPraxis - Developing biosimilars in collaboration with PlantForm (see below) and Fraunhofer.[38]
- Pharming - C1 inhibitor, human collagen 1, fibrinogen (with American Red Cross), and lactoferrin in cow milk[48] The intellectual property behind the fibrinogen project was acquired from PPL Therapeutics when PPL went bankrupt in 2004.[49]
- Phyton Biotech uses plant cell culture systems to manufacture active pharmaceutical ingredients based on taxanes, including paclitaxel and docetaxel[50]
- Planet Biotechnology - antibodies against Streptococcus mutans, antibodies against doxorubicin, and ICAM 1 receptor in tobacco[51]
- PlantForm Corporation - biosimilar trastuzumab in tobacco[52] - It is developing biosimilars in collaboration with PharmaPraxis (see above) and Fraunhofer.[38]
- ProdiGene - was developing several proteins, including aprotinin, trypsin and a veterinary TGE vaccine in corn. Was in process of launching trypsin product in 2002[11] when later that year its field test crops contaminated conventional crops.[12] Unable to pay the $3 million cost of the cleanup, it was purchased by International Oilseed Distributors in 2003[53][54] International Oilseed Distributors is controlled by Harry H. Stine,[55] who owns one of the biggest soybeans genetics companies in the US.[56] ProdiGene's maize-produced trypsin, with the trademark TrypZean[57] is currently sold by Sigma-Aldritch as a research reagent.[10][58][59]
- Syngenta - Beta carotene in rice (this is "Golden rice 2"), which Syngenta has donated to the Golden Rice Project[60]
- University of Arizona - Hepatitis C vaccine in potatoes[61][62]
- Ventria Bioscience - lactoferrin and lysozyme in rice
- Washington State University - lactoferrin and lysozyme in barley[63][64]
- European COST Action on Molecular Farming - COST Action FA0804 on Molecular Farming provides a pan European coordination centre, connecting academic and government institutions and companies from 23 countries.[65] The aim of the Action is to advance the field by encouraging scientific interactions, providing expert opinion and encouraging commercial development of new products. The COST Action also provides grants allowing young scientists to visit participating laboratories across Europe for scientific training.
- Mapp Biopharmaceutical in San Diego, California was reported in August 2014 to be developing ZMapp, an experimental cure for the deadly Ebola virus disease. Two Americans who had been infected in Liberia were reported to be improving with the drug. ZMapp was made using antibodies produced by GM tobacco plants.[66][67]
Projects known to be abandoned
- Agragen, in collaboration with University of Alberta - docosahexaenoic acid and human serum albumin in flax[68][69][70]
- Chlorogen, Inc. - cholera, anthrax, and plague vaccines, albumin, interferon for liver diseases including hepatitis C, elastin, 4HB, and insulin-like growth factor in tobacco chloroplasts. Went out of business in 2007.[71]
- Dow Chemical Company made a deal with Sunol Molecular in 2003 to develop antibodies against tissue factor in plants and in mammalian cell culture and to compare them.[72] In 2005 Sunol sold all its tissue factor antagonists to Tanox,[73][74] which in turn was bought by Genentech in 2003. Genentech licensed the tissue factor program to Altor in 2008[75] Altor is itself a spinout from Sunol.[76] The product under development, ALT-836, formerly known as TNX-832 and Sunol-cH36,[77] is the not the plant-produced antibody, but rather is mammalian antibody, more specifically, a chimeric antibody produced in a hybridoma.[78]
- Epicyte - spermicidal antibodies in corn[79] Epicyte was purchased by Biolex in 2004 at which time Epicyte's portfolio was described as "focused on the discovery and development of human monoclonal antibody products as treatments for a wide range of infectious and inflammatory diseases."[80]
- Large Scale Biology Corporation (LSBC) (bankrupt)[81] - used Tobacco mosaic virus to develop reagents and patient-specific vaccines for Non-Hodgkin's lymphoma, Papillomavirus vaccine, parvovirus vaccine, alpha galactosidase for Fabry disease, lysosomal acid lipase, aprotinin, interferon Alpha 2a and 2b, G-CSF, and Hepatitis B vaccine antigens in tobacco. In 2004, LSBC announced an agreement with Sigma-Aldritch under which LSB would produce recombinant aprotinin in plants of the tobacco family and Sigma-Aldrich would commercially distribute LSBC's recombinant product to its customers in the R&D, cell culture and manufacturing markets.[82] As of October 2012 SIgma still has the protein in stock.[83]
- Meristem Therapeutics - Lipase, lactoferrin, plasma proteins, collagen, antibodies (IgA, IgM), allergens and protease inhibitors in tobacco. Liquidated in 2008.[84]
- Novoplant GmgH - therapeutic proteins in tobacco and feed peas.[85] Conducted field trials in US of feed peas for pigs that produced anti-bacterial antibodies.[86] Former CSO is now with another company;[87] appears that Novoplant is out of business.
- Monsanto Company - abandoned development of pharmaceutical producing corn
- PPL Therapeutics - Alpha 1-antitrypsin for cystic fibrosis and emphysema in sheep milk. This is the company that created Dolly the Sheep, the first cloned animal. Went bankrupt in 2004. Assets were acquired by Pharming[49] and an investment group including University of Pittsburgh Medical Center.[88]
- SemBioSys - insulin in safflower. In May 2012, SemBioSys terminated its operations.[89]
See also[edit]
- Biopharmaceutical
- Bioremediation
- Genetically modified organism
- Polly and Molly
- International Center for Technology Assessment
- ^ Quinion, Michael. "Molecular farming". World Wide Words. Retrieved 2008-09-11.
- ^ a b c d Norris, Sonya (4 July 2005). "Molecular farming". Library of Parliament. Parliament of Canada. PRB 05-09E. Retrieved 2008-09-11.
- ^ Humphreys, John M; Chapple, Clint (2000). "Molecular 'pharming' with plant P450s". Trends Plant Sci. 5 (7): 271–2. doi:10.1016/S1360-1385(00)01680-0. PMID 10871897.
- ^ Miller, Henry I. (2003). "Will we reap what biopharming sows?". Commentary. Nat. Biotechnol. 21 (5): 480–1. doi:10.1038/nbt0503-480. PMID 12721561.
- ^ a b c Kaiser, Jocelyn (25 April 2008). "Is the Drought Over for Pharming?" (PDF). Science 320 (5875): 473–5. doi:10.1126/science.320.5875.473. PMID 18436771.
- ^ a b Sijmons, Peter C.; Dekker, Ben M. M.; Schrammeijer, Barbara et al. (1990). "Production of Correctly Processed Human Serum Albumin in Transgenic Plants". Bio/Technology 8 (3): 217–21. doi:10.1038/nbt0390-217. PMID 1366404.
- ^ Kimbrell, Andrew (2007). Your right to know: Genetic engineering and the secret change in your food. California: Earth Aware Editions. OCLC 74353733.[page needed]
- ^ a b c Twyman, Richard M.; Stoger, Eva; Schillberg, Stefan et al. (2003). "Molecular farming in plants: Host systems and expression technology". Trends Biotechnol. 21 (12): 570–8. doi:10.1016/j.tibtech.2003.10.002. PMID 14624867.
- ^ Ma, Julian K-C.; Drake, Pascal M. W.; Christou, Paul (2003). "Genetic modification: The production of recombinant pharmaceutical proteins in plants". Nature Reviews Genetics 4 (10): 794–805. doi:10.1038/nrg1177. PMID 14526375.
- ^ a b SIgma Info Sheet
- ^ a b "ProdiGene Launches First Large Scale-Up Manufacturing of Recombinant Protein From Plant System" (Press release). ProdiGene. February 13, 2002. Retrieved March 8, 2013.
- ^ a b News of contamination[unreliable source?]
- ^ Biotechnology Regulatory Services Factsheet [Internet]: US Department of Agriculture; c2006. Available from: http://www.aphis.usda.gov/publications/biotechnology/content/printable_version/BRS_FS_pharmaceutical_02-06.pdf
- ^ Boehm, Robert (2007). "Bioproduction of Therapeutic Proteins in the 21st Century and the Role of Plants and Plant Cells as Production Platforms". Annals of the New York Academy of Sciences 1102: 121–34. doi:10.1196/annals.1408.009. PMID 17470916.
- ^ FDA Approval News
- ^ a b c Ma, Julian K -C.; Barros, Eugenia; Bock, Ralph; Christou, Paul; Dale, Philip J.; Dix, Philip J.; Fischer, Rainer; Irwin, Judith et al. (2005). "Molecular farming for new drugs and vaccines". EMBO reports 6 (7): 593–9. doi:10.1038/sj.embor.7400470. PMC 1369121. PMID 15995674.
- ^ Houdebine, Louis-Marie (2009). "Production of pharmaceutical proteins by transgenic animals". Comparative Immunology, Microbiology and Infectious Diseases 32 (2): 107–21. doi:10.1016/j.cimid.2007.11.005. PMID 18243312.
- ^ Dove, Alan (2000). "Milking the genome for profit". Nature Biotechnology 18 (10): 1045–8. doi:10.1038/80231. PMID 11017040.
- ^ Staff (2008) FDA Approves First Human Biologic Produced by GE Animals US Food and Drug Administration, from the FDA Vetenarian Newsletter 2008 Volume XXIII, No VI, Retrieved 10 December 2012
- ^ "Go-ahead for 'pharmed' goat drug". BBC News. June 2, 2006. Retrieved 2006-10-25.
- ^ Büttner-Mainik, Annette; Parsons, Juliana; Jérôme, Hanna; Hartmann, Andrea; Lamer, Stephanie; Schaaf, Andreas; Schlosser, Andreas; Zipfel, Peter F.; Reski, Ralf (2011). "Production of biologically active recombinant human factor H in Physcomitrella". Plant Biotechnology Journal 9 (3): 373–83. doi:10.1111/j.1467-7652.2010.00552.x. PMID 20723134.
- ^ Gasdaska, John R.; Spencer, David; Dickey, Lynn (2003). "Advantages of Therapeutic Protein Production in the Aquatic Plant Lemna". BioProcessing Journal 2 (2): 49–56.
- ^ Baur, Armin; Reski, Ralf; Gorr, Gilbert (2005). "Enhanced recovery of a secreted recombinant human growth factor using stabilizing additives and by co-expression of human serum albumin in the moss Physcomitrella patens". Plant Biotechnology Journal 3 (3): 331–40. doi:10.1111/j.1467-7652.2005.00127.x. PMID 17129315.
- ^ Cox, Kevin M; Sterling, Jason D; Regan, Jeffrey T; Gasdaska, John R; Frantz, Karen K; Peele, Charles G; Black, Amelia; Passmore, David; Moldovan-Loomis, Cristina (2006). "Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor". Nature Biotechnology 24 (12): 1591–7. doi:10.1038/nbt1260. PMID 17128273.
- ^ Decker, Eva L.; Reski, Ralf (2007). "Current achievements in the production of complex biopharmaceuticals with moss bioreactors". Bioprocess and Biosystems Engineering 31 (1): 3–9. doi:10.1007/s00449-007-0151-y. PMID 17701058.
- ^ Protalix website - technology platform
- ^ Gali Weinreb and Koby Yeshayahou for Globes May 2, 2012. FDA approves Protalix Gaucher treatment
- ^ a b c "Molecular Farming – Plant Bioreactors". BioPro. Retrieved 2008-09-13.
- ^ Thomson, JA (2006). Seeds for the future: The impact of genetically modified crops on the environment. Australia: Cornell University Press.[page needed]
- ^ a b c Mandel, Charles (2001-11-06). "Molecular Farming Under Fire". wired. Retrieved 2008-09-13.
- ^ "Protein Products for Future Global Good". molecularfarming.com. Retrieved 2008-09-11.
- ^ Retrieved on 15 May 2007
- ^ Margret Engelhard, Kristin Hagen, Felix Thiele (eds). (2007) Pharming A New Branch of Biotechnology [1]
- ^ Farming for Pharma
- ^ Frauenhofer website
- ^ Pharma Planta website
- ^ FAQ page
- ^ a b c Brennan, Zachary. Brazilian JV looks to tap plant-based manufacturing system for biosimilars. BioPharma-Reporter.com, 23-Jul-2014.
- ^ GTC website
- ^ Press release on opening Halle facility
- ^ a b Icon press release on clinical trial launch
- ^ Iowa State Ag School 2006 Newsletter
- ^ APHIS approval
- ^ Iowa State plant scientists tweak their biopharmaceutical corn research project
- ^ Kentucky Bioprocessing website
- ^ Vezina, Louis-P.; D'Aoust, Marc Andre; Landry, Nathalie; Couture, Manon M.J.; Charland, Nathalie; Barbeau, Brigitte; Sheldon, Andrew J. (2011). "Plants As an Innovative and Accelerated Vaccine-Manufacturing Solution". BioPharm International Supplements 24 (5): s27–30.
- ^ Alfalfa page on Medicago website
- ^ Company website
- ^ a b Press on Pharming Purchase of PPL assets
- ^ Phyton Biotech Official Website
- ^ Company website
- ^ Company website
- ^ Press release from internet archive
- ^ Bloomberg BusinessWeek Profile
- ^ http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=6741964
- ^ Stine Seeds Website
- ^ Trademark listing
- ^ Ray, Kevin; Jalili, Pegah R. (2011). "Characterization of TrypZean: a Plant-Based Alternative to Bovine-Derived Trypsin (Peer-Reviewed)". BioPharm International 24 (10): 44–8.
- ^ Sigma Catalog
- ^ FAQ page
- ^ Arntzen website at UofA
- ^ Khamsi, Roxanne (2005). "Potatoes pack a punch against hepatitis B". News@nature. doi:10.1038/news050214-2.
- ^ "NEPA Decision Summary for Permit #10-047-102r" (PDF). Animal and Plant Health Inspection Service. March 10, 2010.
- ^ Wettstein lab webpage
- ^ COST Action FA0804 Official Website
- ^ Ward, Andrew (8 August 2014) Biotech groups face ethical dilemmas in race for Ebola Cure, Financial Times, Page 4, Internet article retrieved 8 August 2014
- ^ Langreth, Robert, et al (5 August 2014) Ebola Drug Made From Tobacco Plant Saves U.S. Aid Workers Bloomberg News, Retrieved 8 August 2014
- ^ Published PCT Application
- ^ CEO Sam Huttenbauer testified before Congress in 2005 about their GM flax efforts Testimony
- ^ Web search on October 6, 2012 found no website for this company and found that executives are all with other companies.
- ^ Bloomberg BusinessWeek Profile
- ^ Plant production for cancer protein Sept 22, 2003
- ^ Press Release
- ^ Purchase contract
- ^ Press Release
- ^ Altor website
- ^ Clinical trial number NCT00879606 for "Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome" at ClinicalTrials.gov
- ^ Jiao, J.-a.; Kelly, A. B.; Marzec, U. M.; Nieves, E.; Acevedo, J.; Burkhardt, M.; Edwards, A.; Zhu, X.-y.; Chavaillaz, P.-A. (2009). "Inhibition of acute vascular thrombosis in chimpanzees by an anti-human tissue factor antibody targeting the factor X binding site". Thrombosis and Haemostasis 103 (1): 224–33. doi:10.1160/TH09-06-0400. PMC 2927860. PMID 20062929.
- ^ Guardian report Sept 2001
- ^ Trelys press release
- ^ Lamb, Celia (2006-01-13). "Large Scale files Ch. 11 after closing". Sacramento Business Journal. Retrieved 2007-05-10.
- ^ Biomanufacturing Press Release
- ^ Sigma catalog Aprotinin
- ^ History of bankrupt biotech companies
- ^ Cordis entry on Novoplant
- ^ APHIS approval
- ^ Kiprijanov biography
- ^ UPMC buys PPL assets
- ^ Press release May 15, 2012: SemBioSys Announces First Quarter Results and Provides Update on Activities
Further reading[edit]
- Biotech firm puts off rice crop here But company says it plans to sow next year. St. Louis Post-Dispatch. April 29, 2005. Pg. A3.
- Biotech potato provides hepatitis vaccine. The Atlanta Journal-Constitution. February 15, 2005. Pg. 3A.
- Biotechnology Venture Hits Unexpected Snags. New York Times. November 23, 2001. Pg. 5.
- Canadian scientists make insulin from plants: 'Bio-pharming' poised to meet huge diabetes demand at less cost. The Ottawa Citizen. February 27, 2005. Pg. A1.
- GM corn set to stop man spreading his seed. The Observer. September 9, 2001. Pg. 1.
- Pharming plans transgenic first. Financial Times. May 3, 2005. Pg. 18.
- USDA says bio-crop safeguards are tighter ProdiGene is back in Nebraska with test plot. Omaha World Herald. June 2, 2004 Pg. 01D
- Release Permits for Pharmaceuticals, Industrials,Value Added Proteins for Human Consumption,or for Phytoremediation Granted or Pending by APHIS as of March 29, 2006. [2]
External links[edit]
- molecularfarming.com Official site
- Molecular Farming – Plant Bioreactors
- Moss bioreactors do not smell (Interview with Ralf Reski)
- Molecular Pharming - pharmaceuticals with the help of GM plants
- Pharming for Farmaceuticals
- "Pharming the Field: A Look at the Benefits and Risks of Bioengineering Plants to Produce Pharmaceuticals". The Pew Charitable Trusts. July 18, 2002.
- USDA-APHIS Biotechnology Regulatory Services
- EPA Biotechnology page
- FDA Biotechnology page
- Homepage of the Coordinated Framework for Regulation of Biotechnology
- Draft Guidance for APHIS Permits for Field Testing or Movement of Organisms with Pharmaceutical or Industrial Intent
- PlantPharma.org Online Community
- National Science Foundation
- Pharma-Planta Consortium
- Biotechnology Industry Organization
- Biopharmaceuticals.com
- Society for Moleculture, a non-for-profit organisation for plant- factories, Québec, Canada
- PharmCrops


text: RIDGID Tubing Cutting & Reaming Home › Plumbing & Utility Equipment › Pipe Cutting Equipment & Reamers › RIDGID 3/8"-1" Quick Acting CSST Cutter 32078RIDGID 3/8"-1" Quick Acting CSST Cutter 32078 E-mail this product to a friend Pin It Tweet Regular Price: $64.35 On Sale For: $56.63 Shipping Weight: 2lb Quantity: RIDGID The RIDGID® Quick Acting CSST Cutter utilizes many of the well-known design features of the best-in-class Quick Acting Tubing Cutters but adapted specifically for cutting CSST. Cuts corrugated gas tubing sizes 3/8" - 1" diameter. Two sets of split-floating guide wheels*, located on the top and along the sides of the cutter wheel, ride in the corrugations to provide stable tracking, resulting in a high quality cut. The floating guide rollers also serve to hold the two pieces of pipe together to ensure a complete and clean cut. Ergonomic knob provides a firmer grip to cut through tubing quickly. Quick acting mechanism allowing the cutter to rapidly adjust from 3/8" - 1" diameter tubing. Durable I-beam style frame. Shipping Estimator* Shipping estimate for US onlyCountry:United StatesArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBangladeshBelarusBelgiumBelizeBermudaBoliviaBosnia and HerzegowinaBrazilBulgariaCanadaCayman IslandsChileChinaColombiaCosta RicaCroatiaCubaCyprusCzech RepublicDenmarkDominican RepublicEcuadorEgyptFinlandFranceGeorgiaGermanyGibraltarGreeceGuatemalaHong KongHungaryIndiaIndonesiaIrelandIsraelItalyJamaicaJapanJordanKazakhstanKorea, Democratic People's Republic ofKuwaitMalaysiaMexicoNetherlandsNew ZealandNorwayPakistanParaguayPeruPhilippinesPolandPortugalPuerto RicoQatarRomaniaRussiaSaudi ArabiaSingaporeSlovakia (Slovak Republic)SloveniaSouth AfricaSpainSwedenSwitzerlandTaiwanThailandTurkeyUkraineUnited Arab EmiratesUnited KingdomUnited States minor outlying islandsUruguayUzbekistanVenezuelaYugoslaviaState/Province:AA (Armed Forces Americas)AE (Armed Forces Europe)AlabamaAlaskaAlbertaAmerican SamoaAP (Armed Forces Pacific)ArizonaArkansasBritish ColumbiaCaliforniaColoradoConnecticutDelawareDistrict of ColumbiaFederated States of MicronesiaFloridaGeorgiaGuamHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineManitobaMarshall IslandsMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew BrunswickNew HampshireNew JerseyNew MexicoNew YorkNewfoundland and LabradorNorth CarolinaNorth DakotaNorthern Mariana IslandsNorthwest TerritoriesNova ScotiaNunavutOhioOklahomaOntarioOregonOther (Non U.S.)PalauPennsylvaniaPrince Edward IslandPuerto RicoQuebecRhode IslandSaskatchewanSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirgin IslandsVirginiaWashingtonWest VirginiaWisconsinWyomingYukon TerritoryZip:Shipping Estimate: also purchased RIDGID 1/4"-1 5/8" Model 151 Quick-Acting Cutter 31632 RIDGID 1/4" - 1 1/8" Ratchet Handle 118 AUTOFEED Tubing Cutter 32573 RIDGID 223S Stainless Steel Inner/Outer Reamer 1 1/4" 29983 RIDGID 1 1/4"-3 1/2" Model 153 Quick-Acting Cutter 36597


text:
Club Penguin Blog
Blog — What's New
Biker Bunnies and Motor Bugs roll into #WaddleOn episode 27 in the largest cast of players ever assembled for the show! Were you there?
Who likes cookies?!
We've got a special cookie themed episode for you today...check it out!
Happy Friday, Penguins! We have a little surprise for you today...
A few mascots will be online for a little random meetup today at 11:15am Penguin Standard Time! We'll update this blog post with the server a few minutes before the meetup. Thanks to Spike Hike for arranging this little random surprise!
UPDATE: The server for the surprise mascot visit will be... Blizzard!
In other news... I'll be logging on later today for Field Friday, too! I'll be logging onto the server Fjord later today and will update this post with the time for that, too. :)
UPDATE #2: Field Friday will start at 2pm Penguin Standard Time on the server Fjord. I'll be checking out some of the awesome igloos on the island!
Waddle on!
-Club Penguin Team


text:
- About
- Academics
- Admissions & Aid
- Student Life
- Athletics
- Giving
- Evening/Graduate
- Alumni
- News
Bethlehem, Pa., March 17, 2006—Brain Awareness Week at Moravian College, an annual education initiative organized by The Dana Alliance for Brain Initiatives, in collaboration with Moravian's Departments of Biology, Psychology, and Philosophy, and the Moravian Workshop on Artificial Intelligence will culminate on Saturday, March 18 with a brain workshop for teachers and brain-related activities for children in grades K-8 and their families at the Da Vinci Discovery Center of Science in Technology in Allentown, Pa.
A number of brain awareness programs were held earlier this week at Moravian College. Dr. Audrey Ettinger, assistant professor biological sciences at Cedar Crest College presented, "Using Fish to Understand the Nervous System." Dr. Michael L. director of the Rutgers Laboratory for Real-Life Reinforcement Learning, presented "Toward Real-Life Reinforcement Learning,"
Two films are included as part of the organized activities. "Transamerica" was presented and followed by a discussion led by Dr. Stacey Zaremba, professor and chair of the Department of Psychology at Moravian. Students watched the movie "Fast, Cheap, and Out of Control" and participated in a post-film dialogue with Dr. Susan Schneider, assistant professor of philosophy, Moravian College.
In addition to the events, students received daily e-mails throughout the week with brain teasers and fun facts about the brain and nervous system.
The week will conclude with a service learning experience designed by students from Moravian College, Muhlenberg College, Cedar Crest College, and the Da Vinci Discovery Center of Science and Technology. On Saturday, March 18 from 10am-4pm will provide "hands-on" neuroscience activities for children (K-8th grade) and general neuroscience information for their families at the Da Vinci Discovery Center of Science and Technology, Students studying neuroscience from the participating colleges will join their professors in the implementation of the activities. Elementary and middle school teachers in the Lehigh Valley have been invited to participate in the day's events.
Brain Awareness Week is designed to raise the level of public awareness about central nervous system functions as well as recent brain and spinal cord research advancements. The Dana Alliance will release its 2006 Progress Report on Brain Research in the United States at the conclusion of the workshop. Brain Awareness Week activities are sponsored by 1,875 organizations in 65 countries. The next Brain Awareness Week is scheduled for March 12-18, 2007.
Moravian College is a private, coeducational, selective liberal arts college located in Bethlehem, Pennsylvania. Tracing its founding to 1742, it is recognized as America's sixth-oldest college. Visit the website at www.moravian.edu.


text:
Recap |
Photo Gallery 1 |
Photo Gallery 2
2012 Kentucky Baseball
#1 LSU at #2 Kentucky
Apr 21, 2012 at Lexington, Ky. (Cliff Hagan Stadium)
Score by Innings R H E
Kentucky............ 200 400 20X - 8 11 1
Umpires - HP: Morris Hodges 1B: Rickey Armstrong 3B: Tony Maners
Start: 2:08 pm Time: 2:32 Attendance: 2625
J. Grundy faced 1 batter in the 7th.
2012 Kentucky Baseball
#1 LSU at #2 Kentucky
Apr 21, 2012 at Lexington, Ky. (Cliff Hagan Stadium)
LSU starters: 9/cf Fields; 11/3b Hanover; 8/rf Katz; 4/lf Rhymes; 36/ss Nola;
20/dh Snikeris; 26/c Ross; 2/1b Moore; 23/2b Jones, J.; 37/p Eades;
Kentucky starters: 19/cf A. Cousino; 25/3b T. McCarthy; 18/dh A.J. Reed; 21/1b
L. Maile; 11/rf C. Flynn; 2/lf Z. Zellers; 10/2b J.T. Riddle; 35/c M. Williams;
6/ss M. Reida; 22/p J. Grundy;
LSU 1st - Fields singled up the middle (3-1 BBBK).
Hanover grounded out to p, SAC, bunt (0-0); Fields advanced to second. Katz
struck out swinging (1-2 KSBFS). Rhymes doubled to left center, RBI (2-1 BBF);
Fields scored. Rhymes advanced to third on a wild pitch. Nola walked (3-1
BKBBB). Snikeris flied out to rf (1-0 B). 1 run, 2 hits, 0 errors, 2
Kentucky 1st - A. Cousino doubled to right field
(2-1 BSB). A. Cousino advanced to third on a wild pitch. T. McCarthy walked
(3-1 BBBKB). A.J. Reed walked (3-2 BSFFBBB); T. McCarthy advanced to second. L.
Maile flied out to lf, SF, RBI (2-2 KFBFFB); T. McCarthy advanced to third; A.
Cousino scored. C. Flynn singled to center field, RBI (0-1 K); A.J. Reed
advanced to second; T. McCarthy scored. Z. Zellers flied out to lf (0-1 K).
J.T. Riddle popped up to 3b (2-2 FBKB). 2 runs, 2 hits, 0 errors, 2
LSU 2nd - Ross lined out to cf (2-0 BB). Moore
struck out swinging (2-2 BSSBS). Jones, J. walked (3-1 BBKBB). Fields flied out
to lf (0-0). 0 runs, 0 hits, 0 errors, 1 LOB.
Kentucky 2nd - M. Williams singled to left field
(0-2 FK). M. Reida singled, bunt (0-0); M. Williams advanced to second,
advanced to third on a throwing error by 3b. A. Cousino flied out to lf (0-0).
M. Reida out at first c to 2b to 1b, caught stealing. T. McCarthy struck out
swinging (2-2 BKBFS). 0 runs, 2 hits, 1 error, 1 LOB.
LSU 3rd - Hanover popped up to 1b (3-2 KBBKB). Katz
grounded out to 2b up the middle (1-1 KB). Rhymes singled to left center (0-0).
Nola reached on a fielder's choice (0-0); Rhymes out at second ss to 2b.
0 runs, 1 hit, 0 errors, 1 LOB.
Kentucky 3rd - A.J. Reed lined out to cf (0-0). L.
Maile singled to third base (2-2 KFBB). C. Flynn grounded into double play ss
to 2b to 1b (2-2 SBBF); L. Maile out on the play. 0 runs, 1 hit, 0
errors, 0 LOB.
LSU 4th - Snikeris grounded out to 2b (0-0). Ross
grounded out to 2b (1-1 KB). Moore grounded out to 2b (1-1 KB). 0 runs, 0
hits, 0 errors, 0 LOB.
Kentucky 4th - Z. Zellers singled up the middle (2-0
BB). J.T. Riddle hit by pitch (1-2 FK); Z. Zellers advanced to second. M.
Williams singled through the right side, RBI (3-2 BKBBK); J.T. Riddle advanced
to third; Z. Zellers scored. M. Reida popped up to 1b, bunt (0-0). A. Cousino
homered to right center, 3 RBI (2-2 BKBF); M. Williams scored; J.T. Riddle
scored. T. McCarthy singled to left field (2-0 BB). Bonvillain to p for Eades.
A.J. Reed struck out looking (2-2 BFKBK). L. Maile lined out to 2b (0-0).
4 runs, 4 hits, 0 errors, 1 LOB.
LSU 5th - Jones, J. grounded out to 3b (1-1 FB).
Fields lined out to lf (2-1 SBB). Hanover singled up the middle (0-1 K). Katz
singled to right field (0-0); Hanover advanced to second. Rhymes grounded out
to c (1-0 B). 0 runs, 2 hits, 0 errors, 2 LOB.
Kentucky 5th - C. Flynn flied out to lf (2-2 BKBF).
Z. Zellers struck out looking (3-2 BBBKFK). J.T. Riddle flied out to lf (0-2
KS). 0 runs, 0 hits, 0 errors, 0 LOB.
LSU 6th - Nola popped up to 3b (0-0). Snikeris lined
out to cf to right center (2-2 BSFB). Ross singled through the left side (2-2
BFKB). Moore struck out swinging (0-2 KSS). 0 runs, 1 hit, 0 errors, 1
Kentucky 6th - M. Williams grounded out to 2b (0-0).
M. Reida fouled out to 3b (1-2 SKBF). A. Cousino flied out to lf (2-0 BB).
0 runs, 0 hits, 0 errors, 0 LOB.
LSU 7th - Jones, J. walked (3-2 BBKSBB). A. Phillips
to p for J. Grundy. Fields grounded into double play ss to 2b to 1b (2-0 BB);
Jones, J. out on the play. Hanover singled through the right side (1-2 KFB).
Katz flied out to cf (1-2 KFBF). 0 runs, 1 hit, 0 errors, 1 LOB.
Kentucky 7th - T. McCarthy singled to right field
(1-1 BK). A.J. Reed struck out swinging (0-2 KSS). L. Maile homered to right
field, 2 RBI (0-2 FK); T. McCarthy scored. C. Flynn flied out to cf (0-1 K). Z.
Zellers hit by pitch (1-2 FK). J.T. Riddle grounded out to 2b (1-0 B). 2
runs, 2 hits, 0 errors, 1 LOB.
LSU 8th - Rhymes flied out to cf (2-2 BKBK). Nola
singled to center field (1-1 BK). Snikeris lined out to rf (1-2 KSBFF). Nola
advanced to second on a throwing error by c, picked off. Ross lined out to rf
(3-2 BFSBBF). 0 runs, 1 hit, 1 error, 1 LOB.
Kentucky 8th - Berry to p for Bonvillain. M.
Williams grounded out to 3b (2-1 KBB). M. Reida walked (3-2 BBFSBFB). A.
Cousino grounded into double play 1b to ss (1-1 FB); M. Reida out on the play.
0 runs, 0 hits, 0 errors, 0 LOB.
LSU 9th - Edward pinch hit for Moore. Edward flied
out to lf (1-1 BF). Jones, J. flied out to cf (1-0 B). Fields struck out
swinging (1-2 KSBS). 0 runs, 0 hits, 0 errors, 0 LOB.


text:
Page Not Found.
We could not find the page you requested.
This is either because:
- there's an error in the address or link,
- due to a technical fault it has not been properly published,
- it is an older article that has been removed from our site.
Welcome to Sydney Morning Herald Online. Skip directly to: Search Box, Section Navigation, Content. Text Version.
|network map | member centre
[Alexandra Smith] A secret report reveals the State Government is planning to build a rail tunnel under Sydney Harbour and a new line under the city to ease CityRail congestion. more
[Gary Hughes and Tom Allard] Amid secret passwords, mysterious faxes and attempts to protect him from the alleged Chinese spy network he once worked for, Hao Fengjun emerged to talk of the Secret Force. more
[Daniel Lewis] The State Government has drawn up plans to cart water to centres such as Goulburn if no rain falls. more
[Matthew Moore Herald Correspondent in Jakarta] The flamboyant new Jakarta lawyer recruited by Schapelle Corby's legal team says his first move will be to send an appeal for help to the Prime Minister, John Howard. more
An Israeli researcher has challenged the popular belief that Jesus died of blood loss on the cross, saying he probably succumbed to a sometimes fatal disorder now associated with long-haul air travel. more
[Cynthia Banham and Nick O'Malley] Civil liberties and lawyers' groups expressed concerns that the Federal Government's new security checks for airport workers could breach the right of criminal offenders to rehabilitate. more
[John Garnaut] The property market continued to plateau in April, with home lending falling as the air kept leaking out of the housing bubble. more
[Scott Rochfort] The lack of competition on the Qantas-dominated Australia-US route is costing Australia up to $126 million in lost tourist revenue a year, a study commissioned by Singapore Airlines found. more
[12:59am] It may be scant consolation for a failed presidential candidate, but a Webby is a proud achievement for the other victors. more
Tom Cruise and his new film have joined Toyota and the Commonwealth Bank to launch the first interactive TV ads in Australia on Foxtel. more
As Sydney sees another film festival opening, Australia needs to learn the lessons from abroad to halt the slide of its industry, writes Sacha Molitorisz. more
[Greg Prichard] Rugby League Professionals' Association chief Tony Butterfield has organised a meeting to seek assurances the Knights won't fold and leave players unpaid. more
[Greg Growden Chief Rugby Correspondent] Despite a casualty list that moved towards double figures when Stephen Hoiles withdrew from Test selection minutes before yesterday's team announcement, Wallabies coach Eddie Jones had no need to call for painkillers. more
The Aussies kick off an English summer of cricket today. more
The Nine Network and Foxtel have snapped up the rights to next month's Live8 event. more
Snapshots: The world in pictures - every day. more
China's latest dissident has been caught out by a political climate change, writes David McKnight. more
A Virginia sixth-grader has found a defect on his calculator that has prompted Texas Instruments to replace thousands of devices. more
Taronga Zoo's grocery bill is more than one million dollars a year.
Margo Kingston: Webdiary
Radar: Jack Marx Live
Garry Barker: Barker's Byte
Charles Wright: Razor
Booked a getaway for your long weekend yet? Find inspiration here. more
The desire for goods regarded as authentic or timeless is starting to drive retail sales. more
Most viewed articles
From midnight AEST
Most viewed articles
From midnight AEST


text:
Follow us on:
e.g. : beef, steak, seafood, fish, pasta, lobster, cheese
of Origin & Region
Australia, Penola region
St. Mary's
88 pts Robert Parker, Jr.'s The Wine Advocate #168 - Mint, damp earth, black currants, cherries, and spice.
This wine was made to accompany meals in general ranging from a substantial mid-day meal to a light evening snack while listening to music of the moment.
Reviews and other Notes
88 pts Robert Parker, Jr.'s The Wine Advocate #168A primarily Bordeaux blend of Cabernet Sauvignon, Cabernet Franc, and Merlot along with 20% Shiraz, the 2005 Bells & Whistles is a deep ruby/plum-colored, straightforward effort displaying notions of mint, damp earth, black currants, cherries, and spice. It is well-made, ripe, heady, and best drunk over the next 3-4 years.
87 pts Stephen Tanzer's International Wine Cellar 2007 - Ruby-red. Easygoing dark berry and cracked pepper aromas are clear and fresh. Soft and fleshy, with sweet blackberry and cherry preserve flavors, silky tannins and a gentle finish. This is ready to drink.
Winemaker Notes
The Bells and Whistles is a blend made from 65% Cab/Sav, 20% Shiraz, 11% Cab Franc and 4% Merlot grapes grown at St Mary's vineyards. The palate is balanced with a rich smooth persistence.
The batches of grapes used to make this were picked from the different blocks at St Marys as the baume reached 13.2
Grapes were fermented in the small separate batches as they were picked from the vineyard. The wine was extracted from the skins using a basket press. Maturation – 12 months in climate controlled storage.
Total Acid:6.9
Residual Sugar: 0.4
Free/Total Sulfur:18 / 45
Red Blend
| Special
Offers | Price
List | Wineries
| Search
6 Bottle Specials |
Wine Club | Shopping
Cart | Our Friends | FAQ
| Site Map
All prices are reflected in US dollars ( US$ )


text:
Many Italian mathematics teachers are interested in the history of mathematics but very few use it in their classrooms. Why is this? In our opinion, they consider the history of mathematics to be merely a "beautiful story" but don't have time in their classrooms for stories. They must concentrate on improving their students' mathematical skills and understanding. The history of mathematics offers many opportunities for doing mathematics and improving student problem solving skills. Unfortunately, our teachers rarely have the didactical resources to utilize these kinds of activities.
In order to remedy this situation, a collaborative effort to produce suitable materials was established between GREMG, Department of Mathematics, the University of Genoa and IPRASE, Trento, [Provincial Education Research Institute, Trento.] I led a team of consultants and writers including five in-service teachers on this task. Much assistance and encouragement was provided by Prof. Fulvia Furinghetti, Department of Mathematics, University of Genoa. Our goal was to produce a set of historical based activities that could be included into daily classroom instruction. Their integration into the curriculum is intended to promote alternate ways of teaching based on working with historical excerpts and exercises chosen to reinforce (or sometimes even introduce) mathematical competencies.
A two year cooperative effort resulted in the publication of the book: Fare mathematica con i documenti storici. [Doing mathematics with historical documents], 2006, pp168, Adriano Demantté, editor.
A companion text, Volumi per gli insegnanti [Volume for Teachers], provides teaching suggestions, answer keys, topics for further study and bibliography. The student text is comprised of selected documents chosen to expose the work of many important historical authors and also to consider less famous mathematicians whose works were representative of their times. Important Italian secondary school topics are considered. Questions and activities follow after every document. Their role is to focus student attention to the main points in the original document, involving her/him in an active way. The "doing of mathematics" is stressed. Some questions led to further exercises and problems, using different examples or recalling themes in mathematics textbooks. Sometimes students are required to conjecture about the causes of certain historical developments. Teachers using these books can find topics for student discussion and further explorations in mathematics.


text:
Affordable for whom?
There has been a lot of talk from the governor about affordability and school property taxes lately, so I decided to look at some past school tax bills. I have lived in the same house for 20 years and our assessment was substantially raised recently.
It turns out that after the property tax rebate, I paid about 20 percent more in school tax in 1996 and 1997 than I did in 2006. Is this debate occasioned by confusion about the income sensitive rebate system? If so, that will change next year when rebate and tax bill will be one. (It was a stupid system.) However, it may be that something political is going on here.
It sounds to me like Gov. Jim Douglas is trying to use this confusing issue to cast the Democratic majority as the old "tax and spend liberals" but it doesn't seem to be working so well judging by the 233 school budgets that passed on Town Meeting Day. He claimed the numbers were not relevant, but if 60 or 70 towns had rejected their budgets instead of 17 I'm sure the results would have had much more meaning.
All Vermonters want good schools at reasonable prices. Health care reform, unfunded mandates, and cuts in the federal budget to sustain a ridiculous foreign policy are places to start for my money. This partisan bickering does not help. We can't afford to waste time on affordability campaigns.
Tom Doll
What direction will they take us?
As of March 7, 62 towns have passed a resolution to replace Act 60/68. And this has been barely mentioned in the media. You can find out more about property tax relief at www.revoltandrepeal.com. Some papers will not print a web address.
We can hope House Speaker Gaye Symington, D-Jericho, has the resolve and skills to lead the reform. We fear she may not have the will, and will not hear the voices from all of Vermont. We fear she may only hear the voices of the failed Act 60/68 past. Please, Ms. Symington, hear the other voices of today, from across our great state.
Please replace Act 60/68 with education funding, make it fair, make it a lot less complicated — for all of Vermont. Just think, a fair, less complicated funding law for education could be your mark of excellence on our great state. We can have hope, we 62 towns.
Here are some ideas:
• Cap senior citizens' taxes with fixed incomes.
• Level the statewide value of a house — per square foot standard cost — across the state at replacement value. Right now, some towns tax what you may sell your house for in the future, while in another you are taxed less than what you paid for a house today. How can that be?
• Put a cap of 1.5 percent increases per year on the value of any property based on town-wide appraisals since 2006.
Many other states have moved away from using property tax to fund education; what direction will our elected representatives take?
Andrew J. Tarantino
Manchester Center
Campaign finance deform? Not again!
I must condemn in the strongest terms possible the Vermont Legislature's planned campaign finance "deform" (www.vermontguardian.com, March 9) under guise of complying with the U.S. Supreme Court's ridiculous mendacity that money is free speech. I challenge every lawyer in black robes to check out a cart of groceries by convincing the clerk to accept his/her free speech in lieu of cash or debit/credit card.
What the Supremes did, of course, was to misinterpret the Constitution to protect the moneycrats who put them into lifetime sinecures. As a result, Vermont has no elections, only reelections based on name recognition advertising bribe-financed by lobbies unswervingly served by the incumbency. Hence, we have a choice of Democratric and Republican "front-runners" but never any public benefit legislation. We have not forgotten Scatamount, the "bipartisan" health care non-reform to keep private insurers in the doctor business. We have not forgotten the Condos condescension, where property tax rates were lowered but by less than the increase in appraisals, and voters were misled to expect lower tax bills but got bigger ones instead.
We have not forgotten the adamant opposition to wind power to protect the Bush administration's blood-for-oil program by condemning the aesthetics of wind turbines. Nor have we forgotten the hold-harmless policy to benefit corporations whose genetically modified seed racket causes great damage to helpless farmers.
We have also noticed the bait-and-switch campaigning on affordability (higher incomes for the unrich and lower taxes and costs for necessities), and on property tax "reform," quickly forgotten upon the reelection of the Demopublican and Republicratic professional career politicians who waste the short legislative session on extraneous issues (not to offend lucrative lobbies), like the reality of global warming, seat belt law, driver cell phones, transgender tolerance, gay marriage, pill assisted suicide, vaccines for teen girls, mercury in dentistry, medical marijuana, etc.
Real campaign finance reform requires only two provisions: Level the playing field by pooling and evenly dividing the money among candidates for each competitive position, and mandate equal media time as was legislated in the 1932 Fairness Doctrine.
Lastly, public financing is the worst of all options because it burdens the taxpayer unnecessarily and is not based on the candidate's proposed legislative program, offering voters no control and no choice, only the opportunity to recognize familiar names based on the depth of their sponsor's pockets.
Contribution caps and spending limits cannot be monitored, much less enforced, in a nation that can't even conduct a credible election, having twice in a row juggled loser George Pinocchio into the White House.
Peter Moss
Activists are using town meeting
Apparently a very small fraction of Vermont citizens in a small number of towns voted for the troop withdrawal and the impeachment resolutions, but the media, including the Vermont Guardian, are reporting that so many towns adopted the articles, thus implicating that every man, woman, and child of these towns are in favor of these resolutions — which is far from the truth (www.vermontguardian.com, March 9).
Town meetings are being used by activists to leverage their political bias. Rights of free speech are being violated, and the media is promoting this abuse of our town meeting democracy.
David Garrecht
Keep up the good work
We are Vermonters. We are retired and live aboard our sailing yacht in the Mediterranean, and are presently in Turkey.
We just discovered the Vermont Guardian and read with interest the story on impeachment.
Keep up the good work. We will be back in Vermont in a couple of years so keep it how we like it.
Ted Mead
Aboard Rhumb Line
Kemer, Turkey


text:
No Drag and Drop with Preview
Before I got Tiger I was able to drag and drop pictures that I was looking at directly from Preview to wherever I wanted. Now I can't do that. It won't allow me to drag and drop.
Any suggestions? How do you guys get around this annoyance?
Open the preview drawer and you can drag & drop from there to anywhere you wish
see that's the thing. it won't let me do that. it used to, but not anymore. now i get the circle with the X on it saying i can't perform that operation. no clue why that is.
Try going to user library >Preferences > and drag 'com.apple.Preview.plist' to your desktop. Restart and see if preview behaves itself with the new plist file it will make for itself. If it's then OK you can trash the old plist file.
Might be a good idea to get info on Preview app and make sure you can still Read & Write under ownership / permissions.
nope and nope.
tried the reboot with deleting that file, nothing. same problem.
and i have read/write permissions.
other suggestions?
Scraping the bottom of the barrel :)
Check the permissions on your picture folder.
In fact might as well run 'repair permissions' for the whole lot from the disc utility.
Not solved > run Repair from your install disc.
Not Solved > Archive & Install but BACKUP FIRST just in case
|All times are GMT -4. The time now is 01:23 AM.
Powered by vBulletin
Copyright ©2000 - 2015, Jelsoft Enterprises Ltd.


text:
The Daily Star are today reporting on their back page that Arsenal have agreed a fee with Newcastle United for French defender Mathieu Debuchy.
The piece claims that a fee of £12m has been agreed between the two sides and that Arsenal will announce the full-back's signing after the World Cup.
Debuchy, 28, has recently said that he misses playing in the Champions League, something Arsenal can, of course offer him.
The Daily Star, not known for their reliability, do have historic links with Arsenal however. Their late editor was very close friends with Arsenal's former chairman, Peter Hill-Wood. I'm not entirely sure what remains of those ties but they are running this piece as an EXCLUSIVE.
Debuchy would make sense. He is experienced and talented and will be able to slot in to the side without needing any time to get used to the frenetic pace of the Premier League.
Serge Aurier, the other full-back who has been heavily linked with Arsenal [mostly by himself] is still also being linked but it's hard to tell if there is any real Arsenal interest in the player or if it is merely stories based on the player's love of the north London club and his burning desire to play in red and white.
Lee Hurley
Latest posts by Lee Hurley (see all)
- Chelsea manager trolls Arsenal fans - Aug 2, 2015
- Arsenal kill another narrative against Chelsea as Wenger snubs Mourinho - Aug 2, 2015
- Out now: Arsenal's greatest number 7s book - Aug 2, 2015